Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab plus platinum-doublet chemotherapy as first-line treatment for advanced or metastatic non-small cell lung cancer
CTR20191452Phase 3Completed
- Sponsor
- Sanofi
- Start
- Feb 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of cemiplimab in non-small cell lung cancer (NSCLC), sponsored by Sanofi. Started Feb 2020; status: completed.
02
Drugs
cemiplimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20191452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191452.